Patient-Reported Outcomes with Selpercatinib in Patients with *RET*-driven cancers in the Phase 1/2 LIBRETTO-001 Trial

Luis E. Raez, Hyunseok Kang, Yuicihiro Ohe, Manoj Khanal, Kangsu Wang, Yimei Han, Sylwia Szymczak, Scott Barker, Adrienne M. Gilligan,

¹Memorial Cancer Institute/Florida Atlantic University (FAU), Pembroke Pines, FL, USA; ²University of California, San Francisco, CA, USA; ³National Cancer Center Hospital, Tokyo, Japan; ⁴Eli Lilly and Company, Indianapolis, IN, USA; ⁵Tiger Medical Group, Somerset, NJ, USA

Background and Objective

Background

- Selpercatinib is a first-in-class, highly selective, and potent *RE*arranged during Transfection (RET)-kinase inhibitor with central nervous system activity approved for multiple *RET*-activated tumor types¹
- The US FDA recognizes the meaningfulness of health-related quality of life (HRQoL) in oncology trials²
- HRQoL data (December 2019) from the single-arm phase 1/2 LIBRETTO-001 trial was previously described for RET fusion+ nonsmall cell lung cancer (NSCLC) and RETmutant medullary thyroid cancer (MTC)^{3,4}
- Clinically meaningful improvements with selpercatinib were found in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) subscales
- Updated HRQoL data (January 2023) is now available for NSCLC, MTC, as well as for RET-fusion+ thyroid cancer (TC) and RETfusion+ tumor-agnostic (TA) populations


Objective


 To describe patient-reported symptoms and HRQoL in selpercatinib-treated patients with RET-activated cancers using a data

Methods

Study Design and Patient-Reported Outcome Assessment

- Retrospective analysis of data from the LIBRETTO-001 trial
- Patient-reported outcome (PRO) assessed with QLQ-C30⁵
 - A validated PRO measure translated to >100 languages and commonly used in oncology clinical trials





Higher scores on the global health status and functional subscales indicate better functioning. Higher scores on the symptom subscales indicate greater symptom burden

Number of patients who completed the QLQ-C30 may differ from the number of patients who received treatment. Abbreviations: BL – Baseline, CRF – Case Report Form, ECOG PS Eastern Co-operative Oncology Group Performance Status, EOT – End of Treatment, MTC - Medullary Thyroid Cancer, NSCLC - Non-small Cell Lung Cancer, QLQ-C30 - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, RET - REarranged during Transfection, TA – Tumor-agnostic, TC – Thyroid Cancer

Outcomes and Statistical Analyses

Outcomes for all cohorts	Definition/ calculation	Statistical analysis			
QLQ-C30 compliance	Total number of patients who completed QLQ-C30, divided by the total number of patients on treatment at each visit	Descriptive			
Proportion of patients with improved, stable, or worsened status post-BL through cycle 37 for NSCLC and MTC, and through cycle 25 for TC and TA ^a	For symptom subscales: ⁶ Improved - ≥10-point decrease from BL Worsened - ≥10-point increase from BL Stable - being within 10 points from BL For other subscales: ⁶ Improved - ≥10-point increase from BL Worsened - ≥10-point decrease from BL Stable - being within 10 points from BL	Descriptive			
Duration of improvement (DOI)	For symptom subscales: Time from the date of first improvement (10-point decrease from BL) to the date of first deterioration (≥10-point increase after the first improvement) For other subscales: Time from the date of first improvement (10-point increase from BL) to the date of first deterioration (≥10-point decrease after the first improvement)	Kaplan-Meier method. Reported as median (95% CI) number of months.			
Time to first improvement (TTFI)b					
Time to first worsening (TTFW) ^c					

^a Cycle 37 and cycle 25 were chosen for this outcome since the median duration of follow-up for the primary endpoint of the trial (objective response rate), was approximately 37–39 months for NSCLC and MTC, and approximately 28 months for TC and TA. b If there is no first improvement, patients were censored at time to treatment discontinuation or last evaluable disease assessment, whichever occurs first. ^c If there is no first worsening, patients were censored at time to treatment discontinuation or last evaluable disease assessment, whichever occurs first. Abbreviations: BL – Baseline, CI – Confidence Interval, DOI – Duration of Improvement, MTC - Medullary Thyroid Cancer, NSCLC - Non-small Cell Lung Cancer, QLQ-C30 - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, TA – Tumor-agnostic, TC – Thyroid Cancer, TTFI – Time to First Improvement, TTFW – Time to First Worsening

Results

Patient Characteristics in the Cohorts

 At baseline, the NSCLC, MTC, TC, and TA cohorts had 316, 295, 65, and 52 patients, respectively

Parameter		NSCLC (N = 316)	MTC (N = 295)	TC (N = 65)	TA (N = 52)	
Age in years, median (range)		61.0 (23–92)	58.0 (15–90) 59.0 (20–88		54.0 (21–85)	
Sex, n (%)	Male	133 (42.1)	180 (61.0)	32 (49.2)	25 (48.1)	
	Female	183 (57.9)	115 (39.0)	33 (50.8)	27 (51.9)	
ECOG PS, n (%)	0	115 (36.4)	111 (37.6)	25 (38.5)	16 (30.8)	
	1 190 (60		167 (56.6)	36 (55.4)	32 (61.5)	
	2	11 (3.5)	17 (5.8)	4 (6.2)	4 (7.7)	

Abbreviations: ECOG PS - Eastern Co-operative Oncology Group Performance Status, MTC - Medullary Thyroid Cancer, NSCLC - Non-small Cell Lung Cancer, TA - Tumor-agnostic, TC - Thyroid Cancer

QLQ-C30 Compliance Rate

• In the NSCLC, MTC, TC, and TA cohorts, 63.3%, 70.8%, 76.9%, and 73.1% completed the baseline assessment; total compliance rate across all visits was 80.4%, 81.7%, 70.1%, and 85.2%, respectively

Conclusions and Limitations

Conclusions

- PRO measures in LIBRETTO-001 were successfully incorporated with a higher compliance rate across all visits for the QLQ-C30 (≥70%)
- Most patients with RET-activated cancers improved or remained stable on most QLQ-C30 domains during treatment with selpercatinib

Limitations

- LIBRETTO-001 is still ongoing with a median time on treatment of 30.1 months (range: 0.1–66.8) for the overall population
- As cycles of therapy progress, the number of evaluable patients decrease. As a result, the stability of the data may be less reliable

1. Retevmo Prescribing Information. US Food and Drugs Administration, 2022. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. 2. Sitlinger A, et al. Surg Oncol Clin N Am. 2018;27:675–684. 3. Minchom A, et al. Oncologist. 2022;27:22–29. 4. Wirth LJ et al. Oncologist. 2022;27:13-21. 5. Scoring FAQ. EORTC Quality of Life. Available at https://qol.eortc.org/faq-category/scoring/ 6. Osoba D, et al. J Clin Oncol. 1998;16:139-144.

DISCLOSURES

LER or his institution received grants or contracts from Loxo Oncology, Eli Lilly and Company, Genentech, Pfizer, Novartis, Syndax, Guardant, Nanth Health, Natera, BMS, Merck, and Velos. HK's institution has a clinical trial contract with Eli Lilly and Company and Exelixis. He received honorarium from Axis Med. YO received grants or contracts from AstraZeneca, Chugai, Eli Lilly Japan K.K., ONO BMS, Kyorin, Dainippon-Sumitomo, Pfizer, Taiho, Novartis, Takeda, Kissei, Daiichi-Sankyo, Janssen and Loxo Oncology; honoraria for lectures or educational events from AstraZeneca, Chugai, Eli Lilly and Company, ONO, BMS, Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho, Nippon Kayaku, and Kyowa Hakko Kirin; and payment for expert testimony from AstraZeneca, Chugai, ONO, BMS, Kyorin Celltrion, Amgen, Nippon Kayaku, Boehringer Ingelheim, and AnHeart Therapeutics Inc. She holds a leadership or fiduciary role in JSMO, JLCS, and JCOG. KW is an employee of TigerMed Group. MK, YH, SS, SB, and AMG are employees and stockholders of Eli Lilly and Company.

ACKNOWLEDGEMENTS

We would like to thank the clinical trial participants and their caregivers, without whom this work would not be possible. Leo J. Philip Tharappel, an employee of Eli Lilly Services Pvt Ltd, provided medical writing support

Results

Copyright ©2023 Eli Lilly and Company. All rights reserved.

Selpercatinib demonstrated varied TTFI, DOI, and TTFW in QLQ-C30 subscales in all the cohorts

- TTFI ranged from 2.0 to 19.4 months across all cohorts (shorter time to first event is associated with improved outcomes)
- DOI ranged from 1.9 to 28.2 months across all cohorts (longer duration is associated with improved outcomes)
- TTFW ranged from 5.6 to 44.2 months across all cohorts (shorter time to first event is associated with worsening outcomes)

Domain	Subscale	NSCLC		MTC		TC			TA				
		TTFI	DOI	TTFW	TTFI	DOI	TTFW	TTFI	DOI	TTFW	TTFI	DOI	TTFW
GHS		3.7 (2.1, 5.5)	5.6 (3.8; 8.3)	19.1 (11.3; 34.8)	5.5 (3.7; 7.3)	5.6 (3.7; 7.6)	30.4 (15.7; NE)	NE (3.9; NE)	2.8 (1.9; 5.8)	7.5 (3.7; 16.5)	2.0 (1.9; 5.3)	3.8 (2.8; 22.4)	NE (24.9; NE)
Functional domains	Physical	18.5 (7.4; NE)	5.6 (3.8; 7.6)	19.2 (13.8; 31.3)	NE (NE; NE)	9.2 (5.6; 18.4)	NE (25.1; NE)	NE (NE; NE)	6.9 (5.6; 34.3)	16.5 (7.4; 46.8)	4.2 (2.0; NE)	12.0 (3.7; NE)	NE (14.1; NE)
Symptom domains	Fatigue	3.7 (2.1; 3.9)	2.9 (2.1; 3.7)	9.2 (7.0; 11.3)	3.7 (2.1; 3.9)	3.6 (2.8; 3.7)	12.0 (9.1; 22.2)	5.5 (2.6; 22.3)	3.7 (2.0; 5.6)	5.6 (3.7; 10.2)	2.0 (1.9; 19.3)	12.0 (1.9; 25.5)	11.1 (3.9; NE)
	Pain	3.9 (2.1; 9.3)	5.6 (3.7; 6.2)	13.8 (9.5; 17.0)	3.9 (2.3; 11.1)	3.7 (2.8; 5.6)	16.5 (9.2; 22.1)	9.2 (3.7; NE)	3.7 (1.9; 4.7)	11.1 (3.7; 24.0)	3.7 (1.9; NE)	3.7 (1.9; NE)	24.9 (5.8; NE)
Single-item symptom scales	Dyspnea	9.4 (3.7; NE)	5.6 (3.7; 7.6)	44.2 (33.2; NE)	NE (NE; NE)	5.6 (3.7; 12.0)	38.7 (19.5; NE)	16.8 (3.7; NE)	2.6 (1.9; 4.6)	NE (38.0; NE)	NE (NE; NE)	1.9 (1.6; NE)	20.5 (13.7; NE)
	Appetite loss	NE (11.1; NE)	5.8 (4.6; 9.5)	27.5 (16.1; 42.4)	NE (NE; NE)	9.0 (5.6; 14.8)	42.8 (31.0; NE)	NE (NE; NE)	28.2 (3.7; NE)	13.8 (5.6; 36.1)	2.0 (1.9; NE)	NE (1.9; NE)	NE (30.4; NE)
	Sleep disturbance	19.4 (7.5; NE)	5.5 (3.7; 5.8)	31.1 (19.1; NE)	6.5 (3.8; 16.6)	4.1 (3.7; 5.6)	29.5 (19.8; 41.4	11.7 (3.7; NE)	2.8 (1.9; 4.6)	19.4 (9.4; NE)	9.3 (3.7; NE)	5.8 (1.9; NE)	19.4 (13.7; NE)
	Diarrhea	NE (NE; NE)	2.8 (1.9; 5.6)	7.5 (5.8; 11.1)	3.3 (2.0; 5.5)	12.0 (7.4; 17.5)	NE (NE; NE)	NE (NE; NE)	1.9 (1.8; NE)	7.9 (3.8; 18.5)	NE (3.7; NE)	3.9 (1.8; 7.4)	11.1 (3.8; 26.0)

Values reported as median (95% CI) number of months; estimated with Kaplan-Meier method and Greenwood formula. Only clinically relevant parameters were reported. Abbreviations: DOI – Duration of Improvement, MTC -Medullary Thyroid Cancer, NE - Not Estimable, NSCLC - Non-small Cell Lung Cancer, QLQ-C30 - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, TA - Tumor-agnostic, TC -Thyroid Cancer, TTFI – Time to First Improvement, TTFW – Time to First Worsening

CONTACT INFORMATION Dr. Hyunseok Kang - Hyunseok.Kang@ucsf.edu and Adrienne Gilligan - gilligan_adrienne@lilly.com Scan or click the QR code or use this URL (https://lillyscience.lilly.com/congress/esmo2023) for list of all Lilly content presented at the congress. Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.


Other company and product names are trademarks of their respective owners.




cut-off date of January 2023

Proportion of patients with improved, stable, or worsened status through cycle 37 (NSCLC and MTC) or cycle 25 (TC and TA)


• At least 75%, 56%, 83%, and 40% of patients across all the cohorts reported improved or stable QLQ-C30 scores for global health status, symptom scales, functional domains, and symptom domains, respectively through cycle 37 or cycle 25 with selpercatinib use





Life Questionnaire-Core 30, TA – Tumor-agnostic, TC – Thyroid Cancer

Symptom Scales – Dyspnea, Appetite Loss, Sleep Disturbance, and Diarrhea



European Society for Medical Oncology 48th Congress (ESMO); Madrid, Spain; October 20-24, 2023